Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
100 participants
INTERVENTIONAL
2025-03-01
2027-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The DR CRYO study will compare cryo biopsies to forceps biopsies for the diagnosis of peripheral lung lesions.
We hope that the cryo biopsies can improve the diagnostic capabilities of bronchoscopy and provide better biopsies for tumor marker analyses. The project is relevant both for patients undergoing diagnostic work-up for lung cancer in early stages .
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diagnostic Yield of Transbronchial Cryobiopsy in Diagnosis of Interstitial Lung Diseases
NCT02235779
Diagnostic Yield and Safety of Transbronchial Lung Biopsy Using Cryoprobes Versus Conventional Forceps. A Multicenter Study
NCT02464592
Cryobiopsy Vs. Forceps Biopsy for Peripheral Pulmonary Lesions
NCT06752395
CrYobiopsy With Radial UltraSound Guidance
NCT03506295
Prospective, Randomised Multicenter Study Comparing the Efficacy of Transbronchial Forceps Biopsy With Cryobiopsy to Diagnose Interstitial Lung Disease.
NCT01894113
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Lung cancer is currently the leading cause of cancer related deaths world-wide \[1\]. Approximately 5000 people are diagnosed with lung cancer each year in Denmark \[2\]. Lung cancer is often detected in late stages of the disease, which are rarely curable and have a poor prognosis \[3\]. Currently, early stages of lung cancer are often detected incidentally on a computed tomography (CT) scan as a solitary lung lesion \[4\]. Screening for lung cancer has the possibility to reduce lung cancer mortality, however a screening program will produce a large increase in CT scans with lung lesions \[5, 6\]. Tissue sampling is one of the corner stones for correctly diagnosing cancer in a patient. Obtaining tissue from the lungs is challenging since the lungs are difficult to access and biopsies comes with risk of complications.
Tissue samples can be acquired either by removing part of the lung surgically, by performing a needle biopsy through the chest wall or by using a bronchoscope (i.e. by endoscopy)-. The latter has the lowest risk of complications, but currently the diagnostic yield is lower than the other two methods. The low risk profile is an advantage in an increasing elderly population, where improvements in the diagnostic capabilities would be of great value to the patients.
Cryo freezing probes enable sampling from the lung parenchyma by freezing a small tissue area which is then extracted via the bronchoscope. The technology was initially invented to provide larger tissue samples for the diagnosis of interstitial lung disease, but may also be of great value for collecting tissue from cancerous disease since cryo biopsies are generally larger and less crushed than traditional biopsies.
Few studies regarding cryo biopsy for sampling cancer in the lungs exists, however initial trials demonstrates higher diagnostic yield and an increase in sufficient material for tumor marker analysis\[9, 10\].
Hypothesis:
1. Larger biopsies (i.e., cryo biopsies) will increase the diagnostic yield by allowing for sub-optimal sampling position
2. Cryo biopsies are larger and less crushed than forceps biopsies and could therefore increase benign yield to rule out cancer in patients with cancer suspected lesions
3. Using the 1.1 freezing probe for diagnosing malignancy is safe and feasible under conscious sedation.
Objectives:
1. Compare the diagnostic yield of cryo biopsies with forceps biopsies in lesions suspected of malignancy
2. Compare the benign yield/ malignant yield of cryo biopsies with forceps biopsies
3. Compare the number of samples with sufficient material for Next Generation Sequencing (NGS) testing
4. Assess the safety of using the 1.1 mm freezing probe without general anesthesia, tracheal tube or endobronchial blocker.
5. Develop a grading system for endoscopic biopsies to ensure standardized and reproducible assessment.
Method:
This study will be conducted as a randomized clinical trial according to CONSORT guidelines (multicenter) study at Center for Lung Cancer at Odense University Hospital, Bispebjerg Hospital, and Næstved Hospital in collaboration with the Department of Pathology at Odense University Hospital \[11\] .
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
All patient will receive both cryo biopsies and forceps biopsies however the order of the biopsies will be randomized.
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
5 forceps biopsies followed by 5 cryo biopsies
forceps biopsies
5 forceps biopsies
Cryo biosies
5 cryo biopsies
Intervention
5 Cryo biopsies follwed by 5 forcepsbiopsies
forceps biopsies
5 forceps biopsies
Cryo biosies
5 cryo biopsies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
forceps biopsies
5 forceps biopsies
Cryo biosies
5 cryo biopsies
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 or above
* Bronchoscopy with planned forceps sampling from the lesion
Exclusion Criteria
* Not able to provide informed consent.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Southern Denmark
OTHER
Odense University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amanda Dandanell Juul
MD, PhD, Senior researcher
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Næstved Hospital
Næstved, Region Sjælland, Denmark
Odense University Hospital
Odense, Region Syddanmark, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Uffe Bødtger, MD, Professor
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S-20240032
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.